These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 32712155)

  • 1. Comparative analysis of predictive values of the kinetics of 11 circulating miRNAs and of CA125 in ovarian cancer during first line treatment (a GINECO study).
    Robelin P; Tod M; Colomban O; Lachuer J; Ray-Coquard I; Rauglaudre G; Joly F; Chevalier-Place A; Combe P; Lortholary A; Hamizi S; Raban N; Ferron G; Meunier J; Berton-Rigaud D; Alexandre J; Kaminsky MC; Dubot C; Leary A; Malaurie E; You B
    Gynecol Oncol; 2020 Oct; 159(1):256-263. PubMed ID: 32712155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA Trial.
    You B; Robelin P; Tod M; Louvet C; Lotz JP; Abadie-Lacourtoisie S; Fabbro M; Desauw C; Bonichon-Lamichhane N; Kurtz JE; Follana P; Leheurteur M; Piano FD; Ferron G; De Rauglaudre G; Ray-Coquard I; Combe P; Chevalier-Place A; Joly F; Leary A; Pujade-Lauraine E; Freyer G; Colomban O
    Clin Cancer Res; 2020 Sep; 26(17):4625-4632. PubMed ID: 32209570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carboplatin with Decitabine Therapy, in Recurrent Platinum Resistant Ovarian Cancer, Alters Circulating miRNAs Concentrations: A Pilot Study.
    Benson EA; Skaar TC; Liu Y; Nephew KP; Matei D
    PLoS One; 2015; 10(10):e0141279. PubMed ID: 26485143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of high-grade serous ovarian cancer miRNA species associated with survival and drug response in patients receiving neoadjuvant chemotherapy: a retrospective longitudinal analysis using matched tumor biopsies.
    Petrillo M; Zannoni GF; Beltrame L; Martinelli E; DiFeo A; Paracchini L; Craparotta I; Mannarino L; Vizzielli G; Scambia G; D'Incalci M; Romualdi C; Marchini S
    Ann Oncol; 2016 Apr; 27(4):625-34. PubMed ID: 26782955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum CA125 levels predict outcome of interval debulking surgery after neoadjuvant chemotherapy in patients with advanced ovarian cancer.
    Zhang D; Jiang YX; Luo SJ; Zhou R; Jiang QX; Linghu H
    Clin Chim Acta; 2018 Sep; 484():32-35. PubMed ID: 29702068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic Model of Serum miR-193a-5p, HE4 and CA125 Improves the Diagnostic Efficacy of Epithelium Ovarian Cancer.
    Ren X; Zhang H; Cong H; Wang X; Ni H; Shen X; Ju S
    Pathol Oncol Res; 2018 Oct; 24(4):739-744. PubMed ID: 29520570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant chemotherapy with or without nintedanib for advanced epithelial ovarian cancer: Lessons from the GINECO double-blind randomized phase II CHIVA trial.
    Ferron G; De Rauglaudre G; Becourt S; Delanoy N; Joly F; Lortholary A; You B; Bouchaert P; Malaurie E; Gouy S; Kaminsky MC; Meunier J; Alexandre J; Berton D; Dohollou N; Dubot C; Floquet A; Favier L; Venat-Bouvet L; Fabbro M; Louvet C; Lotz JP; Abadie-Lacourtoisie S; Desauw C; Del Piano F; Leheurteur M; Bonichon-Lamichhane N; Rastkhah M; Follana P; Gantzer J; Ray-Coquard I; Pujade-Lauraine E
    Gynecol Oncol; 2023 Mar; 170():186-194. PubMed ID: 36706645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment strategies for patients with advanced ovarian cancer undergoing neoadjuvant chemotherapy: interval debulking surgery or additional chemotherapy?
    Yoneoka Y; Ishikawa M; Uehara T; Shimizu H; Uno M; Murakami T; Kato T
    J Gynecol Oncol; 2019 Sep; 30(5):e81. PubMed ID: 31328461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CA125 kinetic parameters predict optimal cytoreduction in patients with advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy.
    Pelissier A; Bonneau C; Chéreau E; de La Motte Rouge T; Fourchotte V; Daraï E; Rouzier R
    Gynecol Oncol; 2014 Dec; 135(3):542-6. PubMed ID: 25223808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Confirmation of the utility of the CA-125 elimination rate (KELIM) as an indicator of the chemosensitivity in advanced-stage ovarian cancer in a "real-life setting".
    van Wagensveld L; Colomban O; van der Aa MA; Freyer G; Sonke GS; Kruitwagen RFPM; You B
    J Gynecol Oncol; 2024 May; 35(3):e34. PubMed ID: 38216134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of CA-125 re-elevation after interval debulking surgery in patients with advanced-stage ovarian cancer undergoing neoadjuvant chemotherapy.
    Lee YJ; Chung YS; Lee JY; Nam EJ; Kim SW; Kim S; Kim YT
    Eur J Surg Oncol; 2019 Apr; 45(4):644-649. PubMed ID: 30337203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum HE4 superior to CA125 in predicting poorer surgical outcome of epithelial ovarian cancer.
    Shen Y; Li L
    Tumour Biol; 2016 Nov; 37(11):14765-14772. PubMed ID: 27629144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Postoperative human epididymis protein 4 predicts primary therapy outcome in advanced epithelial ovarian cancer.
    Vallius T; Hynninen J; Auranen A; Matomäki J; Oksa S; Roering P; Grènman S
    Tumour Biol; 2017 Feb; 39(2):1010428317691189. PubMed ID: 28218038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carboplatin re-treatment in platinum-resistant epithelial ovarian cancer patients.
    Hansen MKG; Smerdel MP; Waldstrøm M; Andersen RF; Adimi P; Jakobsen A; Steffensen KD
    Cancer Chemother Pharmacol; 2020 Dec; 86(6):751-759. PubMed ID: 33067703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Diagnostic and prognostic value of tumor markers, scores (clinical and biological) algorithms, in front of an ovarian mass suspected of an epithelial ovarian cancer: Article drafted from the French Guidelines in oncology entitled "Initial management of patients with epithelial ovarian cancer" developed by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY under the aegis of CNGOF and endorsed by INCa].
    Bendifallah S; Body G; Daraï E; Ouldamer L
    Gynecol Obstet Fertil Senol; 2019 Feb; 47(2):134-154. PubMed ID: 30733191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Single-Center, Retrospective Study of Bevacizumab-Containing Neoadjuvant Chemotherapy followed by Interval Debulking Surgery for Ovarian Cancer.
    Park J; Eoh KJ; Nam EJ; Kim S; Kim SW; Kim YT; Lee JY
    Yonsei Med J; 2020 Apr; 61(4):284-290. PubMed ID: 32233170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of various kinetic parameters of CA-125 in patients with advanced-stage ovarian cancer undergoing neoadjuvant chemotherapy.
    Lee YJ; Lee IH; Kim YJ; Chung YS; Lee JY; Nam EJ; Kim S; Kim SW; Kim YT
    PLoS One; 2018; 13(9):e0203366. PubMed ID: 30188915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The lack of significance of Ca125 response in epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and delayed primary surgical debulking.
    Le T; Hopkins L; Faught W; Fung-Kee-Fung M
    Gynecol Oncol; 2007 Jun; 105(3):712-5. PubMed ID: 17400284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum CA 125 Level after Neoadjuvant Chemotherapy is Predictive of Prognosis and Debulking Surgery Outcomes in Advanced Epithelial Ovarian Cancer.
    Matsuhashi T; Takeshita T; Yamamoto A; Kawase R; Yamada T; Kurose K; Doi D; Konnai K; Onose R; Kato H
    J Nippon Med Sch; 2017; 84(4):170-176. PubMed ID: 28978897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Potential value of CA125 kinetic monitoring in the initial management of advanced epithelial ovarian cancer].
    Vignot S; Brochet C; Debord C; Lauratet B; Bernard M
    Ann Biol Clin (Paris); 2011; 69(5):597-604. PubMed ID: 22008142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.